Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Shares Issued (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Shares Issued for 12 consecutive years, with $228000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 93.99% to $228000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 33.39% increase, with the full-year FY2025 number at $7.2 million, up 33.39% from a year prior.
  • Shares Issued was $228000.0 for Q4 2025 at Niagen Bioscience, up from $152000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $24.9 million in Q1 2021 to a low of -$15.8 million in Q2 2021.
  • A 4-year average of $3.9 million and a median of $2.1 million in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 18741.67% in 2021; the steepest drop was 435.46% in 2021.
  • Niagen Bioscience's Shares Issued stood at $17.4 million in 2021, then plummeted by 55.41% to $7.7 million in 2022, then tumbled by 51.06% to $3.8 million in 2024, then crashed by 93.99% to $228000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Shares Issued are $228000.0 (Q4 2025), $152000.0 (Q3 2025), and $3.8 million (Q2 2025).